Do you know what…?
Why would fighting dengue mean breeding more mosquitoes?
AI-generated image, not a photograph. This edition's article, audio and test are AI-generated and published automatically without prior human review. Sources · Editorial & AI Policy
Listen to today’s article
In Yogyakarta, Indonesia, researchers tested a counterintuitive defence against dengue: releasing mosquitoes rather than simply killing them. Their Aedes aegypti carried wMel, a strain of the bacterium Wolbachia that makes these mosquitoes less susceptible to dengue-virus infection. The trial, published in 2021, randomly assigned 12 geographic clusters to releases and 12 to no releases; both groups continued routine mosquito control. Institutional reports from the research team described approximately 86% fewer dengue hospitalisations in treated areas than in untreated areas. The crucial distinction is population replacement, not population elimination: changing the mosquito's capacity to transmit disease can protect people without removing the insect.
That reversal explains an apparently improbable industrial product: mosquito eggs. According to Brazil's Ministry of Health, the Wolbachia facility inaugurated in Curitiba in July 2025 had a reported production capability of 100 million eggs per week. Released mosquitoes reproduce with wild mosquitoes, establishing successive generations with reduced transmission ability. The strategy therefore seeks to make a biological change persist beyond the initial releases. Yet factory capacity and public-health protection are not . The reported capability does not establish output, completed deployments or measured benefits. Manufacturing eggs is ; the outcome that matters is less disease.
Brazil's Ministry of Health reported investment exceeding R$82 million in the Curitiba facility in 2025, illustrating the infrastructure needed to translate field research into deployment. That expenditure is not a measure of healthcare savings, and the Indonesian result does not establish Brazilian effectiveness. The Yogyakarta trial used a test-negative design, comparing deployment exposure among patients testing positive or negative for dengue, rather than relying solely on laboratory virus blocking. Its local benefits cannot guarantee identical protection elsewhere. The challenge is to reproduce those benefits across varied communities, alongside routine control and clinical care—not to declare mosquitoes harmless or dengue defeated.